Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...

Omeros Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

The U.S. FDA has approved narsoplimab (Yartemlea) as the first indicated therapy for hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults and children aged ...

Omeros (OMER) announced that the U.S. Food and Drug Administration, FDA, has approved YARTEMLE for the treatment of hematopoietic stem cell ...

Nigeria entered a new phase in its education journey with the rollout of the revised national curriculum in 2025. The reform ...

Access to capital remains one of the most persistent constraints facing entrepreneurs, investors, and institutions. Despite ...

Belize Proposes $500,000 Investor Fast-Track to Permanent Residency. Belize has signaled a major policy transformation: a ...

Aavishkaar Group is recalibrating its climate investment strategy to balance long-term carbon sequestration projects with ...

The FDA approval clears the path for a U.S. launch in January 2026. ・Trial and expanded access data showed strong response rates and short-term survival in high-risk patients. ・Yartemlea becomes the ...

The Chicago Bears are expanding their search for a new stadium to Northwest Indiana, even though they already own land in Arlington Heights and have also proposed a new lakefront stadium in Chicago.